Eli Lilly and Co (MEX:LLY) Cash Received from Insurance Activities


MEX:LLY Eli Lilly and Co MEX:LLY
97 GF Score
Price MXN19,495.00
GF Value MXN24,745.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cash Received from Insurance Activities?

Cash Received from Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.

MEX:LLY
97GF Score
Eli Lilly and Co MEX:LLY
Cash Received from Insurance Activities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (MEX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of MXN19,495.00 is trading 21.2% below its estimated GF Value™ of MXN24,745.36. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for MEX:LLY:

  • Cash Received from Insurance Activities:
  • GF Value™: MXN24,745.36 vs. price of MXN19,495.00 (21.2% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the MEX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for MEX:LLY

Cash Received from Insurance Activities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN19,495.00
Price
MXN24,745.36
GF Value